NRx Pharmaceuticals, Inc. announced the date for its 2025 Annual Meeting.
The meeting is scheduled for March 23, 2026, at 10:00 a.m. Eastern Time in a virtual-only format.
Stockholders of record as of February 12, 2026, are entitled to notice and vote at the meeting.
Annual Meeting Details
The 2025 Annual Meeting will be held on March 23, 2026, in a virtual-only format at 10:00 a.m. Eastern Time.
Record Date
Stockholders of record as of February 12, 2026, are eligible to receive meeting notifications and participate in voting.
Submission Deadlines
Stockholder proposals and nominations must be submitted by January 26, 2026, to be considered for the 2025 Annual Meeting.
Notice Requirements
Proposals submitted under Rule 14a-8 must adhere to specific requirements and deadlines set forth by the Exchange Act.
Delivery Instructions
Written proposals and director nominations should be delivered exclusively by hand or certified/registered mail to NRx Pharmaceuticals, Inc.
- NRx Pharmaceuticals is focusing on developing therapeutics for central nervous system disorders like suicidal depression, chronic pain, and PTSD.
- The Company's NRX-100 and NRX-101 have received Fast Track and Breakthrough Therapy Designations respectively for treating depression.
- NRx Pharmaceuticals has filed for multiple drug applications, aiming to address suicidal ideation in patients with depression.
The announcement of NRx Pharmaceuticals' 2025 Annual Meeting date and record date reflects the Company's commitment to transparency and shareholder engagement in its decision-making processes.